16 studies found for:    amicus, fabry
Show Display Options
Rank Status Study
1 Recruiting Physician Initiated Request for Migalastat in Individual Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl
2 Completed Study of the Effects of Oral AT1001 (Migalastat Hydrochloride) in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Drug: Placebo
3 Completed A Phase 1 Study To Evaluate the Safety of Migalastat Hydrochloride Given Intravenously to Healthy Volunteers
Condition: Fabry Disease
Interventions: Drug: IV migalastat HCl;   Drug: IV placebo;   Drug: oral migalastat HCl
4 Not yet recruiting Open-Label Extension Study of the Long-Term Effects of Migalastat HCL in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150 mg
5 Completed Open Label Long-term Safety Study of AT1001 in Patients With Fabry Disease Who Have Completed a Previous AT1001 Study
Condition: Fabry Disease
Intervention: Drug: AT1001
6 Active, not recruiting Study to Compare the Efficacy and Safety of Oral AT1001 and Enzyme Replacement Therapy in Patients With Fabry Disease
Condition: Fabry Disease
Interventions: Drug: migalastat hydrochloride;   Biological: agalsidase
7 Completed Drug-Drug Interaction Study Between AT1001 and Agalsidase in Subjects With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001
8 Completed A Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
9 Recruiting Open-Label Phase 3 Long-Term Safety Study of Migalastat
Condition: Fabry Disease
Intervention: Drug: migalastat HCl 150mg
10 Completed A Study to Assess the Absorption, Metabolism and Excretion of Migalastat Hydrochloride (AT1001-014)
Condition: Fabry Disease
Intervention: Drug: [14C] AT1001
11 Completed A Phase I, Randomized, Single-Blind, Four-Period Cross-Over, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety and Pharmacokinetics of Single Oral Doses of GR181413A/AT1001 in Healthy Japanese Subjects
Condition: Fabry Disease
Interventions: Drug: GR181413A/AT1001 solution;   Drug: GR181413A/AT1001 capsule;   Other: Potable water;   Drug: Placebo capsule
12 Completed Safety and Pharmacokinetics of AT1001 (Migalastat HCl) in Healthy Subjects and Subjects With Impaired Renal Function
Condition: Fabry Disease
Intervention: Drug: AT1001 150 mg
13 Completed A 24-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
14 Completed A 12-Week Safety and Pharmacodynamic Study of AT1001 in Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
15 Completed A 12-Week Safety and Pharmacodynamic Study of AT1001 in Female Patients With Fabry Disease
Condition: Fabry Disease
Intervention: Drug: AT1001 (migalastat hydrochloride)
16 Completed Migalastat Food Effect Study
Condition: Fabry Disease
Interventions: Drug: A (migalastat);   Drug: B (migalastat);   Drug: C (migalastat);   Drug: D (migalastat);   Drug: E (migalastat)

Indicates status has not been verified in more than two years